Vaccine Safety Working Group Update

National Vaccine Advisory Committee February 16th, 2011

Dr. Marie McCormick
Co-Chair, Vaccine Safety Working Group

Members

- Robert Ball (FDA)
- Norman Baylor (FDA)
- Jessica Bernstein (NIH)
- Robert L. Beck
- Guthrie S. Birkhead*
- Tawny Buck^
- Chris Carlson
- Vito Caserta (HRSA)
- Vicky Debold
- Cornelia Dekker
- Geoffrey Evans (HRSA)
- Mark Feinberg
- Steve Goodman
- Lance Gordon
- Lawrence Gostin (as needed)

- Rita Helfand (CDC)
- Sean Hennessy
- Clement Lewin
- James O. Mason
- Marie McCormick^
- Gerald Medoff
- Karen Midthun (FDA)
- Barbara Mulach (NIH)
- Andrew Pavia^
- William Raub
- L.J. Tan
- Melinda Wharton (CDC)
- Cindy Weinbaum (CDC)

^{*}Chair of NVAC

[^]Co-Chair of Vaccine Safety Working Group

Charge 2


"To review the current federal vaccine safety system and develop a White Paper describing the infrastructure needs for a federal vaccine safety system to fully characterize the safety profile of vaccines in a timely manner, reduce adverse events whenever possible, and maintain and improve public confidence in vaccine safety."

Working Group Process

- Monthly (+) working group conference calls
- Additional sub-group conference calls
- Correspondence via phone/email
- 3 in person meetings
- Proposed stakeholder engagement meeting
- Public comment solicitation

NVAC Vaccine Safety Working Group





Information Gathering Charge 2 Kick-Off Meeting

- July 15-16, 2009
- Invited 26 panelists to speak on:
 - Principles and policy alternatives for a robust vaccine safety system
 - Identifying innovative ways of overcoming gaps in vaccine safety science infrastructure
 - The ideal system to meet the needs of the public, public health, and healthcare professionals for confidence in vaccine safety
 - Lessons from other safety arenas
 - Enhancing the adoption and implementation of the NVAC white paper

VSWG Subgroups

Content Subgroups

- 1. Structure/Governance (Bill Raub)
- 2. Epidemiology/Surveillance of Adverse Events (Lance Gordon)
- 3. Biological Mechanisms of Adverse Events (LJ Tan)

Process Subgroups

- 1. Stakeholder Engagement
- 2. Implementation

Briefings

- ASTHO Public Confidence study
- Barcoding technology
- CDC Immunization Safety Office
- CISA Biospecimen Repository
- CISA Investigators
- DoD Vaccine Healthcare Centers
- DoD Milvax Drug safety systems
- FDA/CBER
- International vaccine safety systems


- Manufacturers (VSWG members)
- NIH/NIAID
- Past IOM vaccine safety review committee consideration of biological mechanisms
- Post-Licensure Immunization Safety Monitoring (PRISM)
- VSD Investigators
- VA

Information Gathering Salt Lake City Meeting


- April, 2010
- 29 federal and non-federal stakeholders, including 9 VSWG members
- Issues discussed:
 - Opportunities for improvement in the current vaccine safety system
 - Proposed evaluation criteria
 - Strengths and weaknesses of various enhancements or alterations to the structure and governance of the vaccine safety system

Complexity of the System

Vaccine Safety Activities & Primary Purposes by Group with Lead Role



NVAC Vaccine Safety Working Group Work to Data (continued)




Working Draft sections

- Introduction
 - Current coverage levels
 - Successes in the current vaccine safety system
 - Opportunities in the current vaccine safety system
- Organization and Methods of the VSWG
- Findings and Results
 - Background
 - Prior recommendations
 - Review of the current vaccine safety system
 - Stakeholder and public input
- Discussion/Conclusions
- Goals of an ideal vaccine safety system
- Recommendations of the VSWG

Draft Report – 2011 process points

- Current V0.9 of the draft report is being reviewed, discussed and revised within the working group
- Late February Full draft report v1.0 to be distributed to NVAC members and Federal Agencies
- Late March Comments on v1.0 received from NVAC/Agencies
- Mid April draft v2.0 open for public comment via Federal Register Notice
- April 18 (tentative) Open stakeholder meeting for input on draft v2.0
- Mid May Public Comment session on v2.0 closes
- Early June v3.0 distributed for discussion at June NVAC meeting
- September NVAC vote on VSWG Charge 2 White Paper

NVAC Vaccine Safety Working Group Draft Timeline



Next Steps

- Feedback from the NVAC and Federal Agencies
- Gather stakeholder and public input
- Recommendation evaluation process
- Revise report for June 2011 NVAC discussion and September 2011 vote.